Business

Danaher succeeds after cutting Covid-related revenue from growth reports


medical company

Danaher

The company’s fourth-quarter earnings beat expectations, but the stock fell early Tuesday. This is due to first-quarter guidance and a reassessment of its earnings report, according to analysts at RBC Capital Markets.

In the face of fluctuations in demand for Covid-19 related products,

Danaher

(ticker: DNR) has adjusted its definition of revenue growth to exclude those items, starting in the first quarter of 2023, according to the company’s earnings report. On that basis, the medical company forecasts average single-digit revenue growth for the first quarter and high single-digit growth for the whole of 2023.

news7f

News7F: Update the world's latest breaking news online of the day, breaking news, politics, society today, international mainstream news .Updated news 24/7: Entertainment, Sports...at the World everyday world. Hot news, images, video clips that are updated quickly and reliably

Related Articles

Back to top button